DZ3308A1 - 5-alkylpyrido [2,3-d] pyrimidin tyrosine kinase inhibitoren - Google Patents

5-alkylpyrido [2,3-d] pyrimidin tyrosine kinase inhibitoren

Info

Publication number
DZ3308A1
DZ3308A1 DZ013308A DZ013308A DZ3308A1 DZ 3308 A1 DZ3308 A1 DZ 3308A1 DZ 013308 A DZ013308 A DZ 013308A DZ 013308 A DZ013308 A DZ 013308A DZ 3308 A1 DZ3308 A1 DZ 3308A1
Authority
DZ
Algeria
Prior art keywords
alkylpyrido
pyrimidines
tyrosine kinase
kinase inhibitors
inhibitors
Prior art date
Application number
DZ013308A
Other languages
English (en)
French (fr)
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of DZ3308A1 publication Critical patent/DZ3308A1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DZ013308A 2000-03-06 2001-01-29 5-alkylpyrido [2,3-d] pyrimidin tyrosine kinase inhibitoren DZ3308A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18712400P 2000-03-06 2000-03-06
PCT/US2001/002657 WO2001070741A1 (en) 2000-03-06 2001-01-29 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
DZ3308A1 true DZ3308A1 (de) 2001-09-27

Family

ID=22687699

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ013308A DZ3308A1 (de) 2000-03-06 2001-01-29 5-alkylpyrido [2,3-d] pyrimidin tyrosine kinase inhibitoren

Country Status (36)

Country Link
EP (1) EP1268476A1 (de)
JP (1) JP2003528101A (de)
KR (1) KR20020075805A (de)
CN (1) CN1422268A (de)
AP (1) AP2002002643A0 (de)
AR (1) AR034119A1 (de)
AU (1) AU2001233028A1 (de)
BG (1) BG107161A (de)
BR (1) BR0109056A (de)
CA (1) CA2401368A1 (de)
CO (1) CO5280200A1 (de)
CR (1) CR6736A (de)
CZ (1) CZ20022929A3 (de)
DZ (1) DZ3308A1 (de)
EA (1) EA200200802A1 (de)
EE (1) EE200200506A (de)
GT (1) GT200100037A (de)
HN (1) HN2001000040A (de)
HR (1) HRP20020798A2 (de)
HU (1) HUP0300136A2 (de)
IL (1) IL151480A0 (de)
IS (1) IS6524A (de)
MA (1) MA26881A1 (de)
MX (1) MXPA02008535A (de)
NO (1) NO20024235L (de)
NZ (1) NZ520962A (de)
OA (1) OA12227A (de)
PA (1) PA8513201A1 (de)
PE (1) PE20011177A1 (de)
PL (1) PL358271A1 (de)
SK (1) SK12472002A3 (de)
SV (1) SV2001000338A (de)
TN (1) TNSN01036A1 (de)
WO (1) WO2001070741A1 (de)
YU (1) YU66502A (de)
ZA (1) ZA200207110B (de)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
EP1333833B1 (de) 2000-10-23 2011-08-24 GlaxoSmithKline LLC Neues trisubstitutiertes 8H-Pyrido[2,3-d]pyrimidin-7-onderivat zur Behandlung von durch CSBP/p38kinase vermittelten Krankheiten
WO2002064594A2 (en) * 2001-02-12 2002-08-22 F. Hoffmann-La Roche Ag 6-substituted pyrido-pyrimidines
EP1364950A4 (de) * 2001-02-26 2005-03-09 Tanabe Seiyaku Co Pyridopyrimidin- und naphthyridinderivate
US20030105115A1 (en) * 2001-06-21 2003-06-05 Metcalf Chester A. Novel pyridopyrimidines and uses thereof
US20030100572A1 (en) * 2001-06-21 2003-05-29 Ariad Pharmaceuticals,Inc. Novel pyridopyrimidones and uses thereof
GEP20063909B (en) * 2002-01-22 2006-08-25 Warner Lambert Co 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d] PYRIMIDIN-7-ONES
BR0309053A (pt) 2002-04-19 2005-02-22 Smithkline Beecham Corp Compostos
CA2494061C (en) 2002-07-31 2011-06-14 Wayne R. Danter Protein tyrosine kinase inhibitors
US7629347B2 (en) 2002-10-09 2009-12-08 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
EP1590341B1 (de) * 2003-01-17 2009-06-17 Warner-Lambert Company LLC 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
WO2005020921A2 (en) * 2003-08-29 2005-03-10 Exelixis, Inc. C-kit modulators and methods of use
ES2281843T3 (es) 2003-11-13 2007-10-01 F. Hoffmann-La Roche Ag Pirido-7-pirimidin-7-onas sustituidas con hidroxialquilo.
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
FR2873118B1 (fr) 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
EP1630163A1 (de) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
JP2008510770A (ja) * 2004-08-26 2008-04-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｌｋ阻害剤としての新規プテリジノン
DE102004058337A1 (de) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
CA2594860A1 (en) 2005-01-14 2006-07-20 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity
JP2008535822A (ja) 2005-03-25 2008-09-04 グラクソ グループ リミテッド 新規化合物
CN101495475A (zh) 2005-03-25 2009-07-29 葛兰素集团有限公司 制备吡啶并[2,3-d]嘧啶-7-酮和3,4-二氢嘧啶并[4,5-d]嘧啶-2(1H)-酮衍生物的方法
TW200724142A (en) 2005-03-25 2007-07-01 Glaxo Group Ltd Novel compounds
AR053346A1 (es) 2005-03-25 2007-05-02 Glaxo Group Ltd Compuesto derivado de 8h -pirido (2,3-d) pirimidin -7 ona 2,4,8- trisustituida composicion farmaceutica y uso para preparar una composicion para tratamiento y profilxis de una enfermedad mediada por la quinasa csbp/ rk/p38
US7737155B2 (en) * 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
FR2887882B1 (fr) 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
TW200800983A (en) 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
AU2006302148B2 (en) * 2005-10-07 2012-12-06 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kalpha
EP1940839B1 (de) * 2005-10-07 2013-07-31 Exelixis, Inc. PYRIDOPYRIMIDINONVERBINDUNGEN ALS INHIBITOREN VON PI3Kalpha
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
JP4718637B2 (ja) 2006-09-15 2011-07-06 ファイザー・プロダクツ・インク ピリド（２，３−ｄ）ピリミジノン化合物およびｐｉ３阻害剤としてのその使用
AU2007311480A1 (en) * 2006-10-16 2008-04-24 Forma Therapeutics, Inc. Pyrido [2, 3-d] pyrimidines and their use as kinase inhibitors
EP1914234A1 (de) * 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidinen und ihre Verwendung als kinase Inhibitoren
WO2008055013A2 (en) * 2006-10-31 2008-05-08 Janssen Pharmaceutica N.V. 5-oxo-5,8 - dihydro - pyrido - pyrimidines as inhibitors of c-fms kinase
FR2910813B1 (fr) 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
UA101611C2 (ru) * 2007-04-03 2013-04-25 Аррей Байофарма Инк. СОЕДИНЕНИЯ ИМИДАЗО[1,2-а]ПИРИДИНА КАК ИНГИБИТОРЫ ТИРОЗИНКИНАЗЫ РЕЦЕПТОРОВ
RU2010101052A (ru) * 2007-06-15 2011-07-20 Банью Фармасьютикал Ко., Лтд (Jp) Производные бициклоанилина
WO2009019205A1 (en) 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Crystalline form of a dihydropteridione derivative
MX2010006457A (es) 2007-12-19 2010-07-05 Amgen Inc Compuestos fusionados de piridina, pirimidina y triazina como inhibidores de ciclo celular.
WO2009079797A1 (en) 2007-12-26 2009-07-02 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
EP2100894A1 (de) * 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidinone verwendbar als Plk1 (polo-like kinase) Hemmen
AU2009233951B2 (en) * 2008-04-07 2014-02-27 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
EP2112150B1 (de) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Verbesserte Raf-Inhibitoren
CA2730890C (en) 2008-07-17 2018-05-15 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
US8101622B2 (en) 2008-09-30 2012-01-24 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kα and mTOR
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
CA2776770A1 (en) * 2009-10-09 2011-04-14 Afraxis, Inc. 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
KR101754664B1 (ko) 2009-12-18 2017-07-06 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 치환된 피리도〔2,3-ｄ〕피리미딘-7(8ｈ)-온스 및 이의 치료 용도
US8901137B2 (en) 2010-02-09 2014-12-02 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors
CA2999435A1 (en) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
KR101434841B1 (ko) * 2010-08-05 2014-08-29 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 2-치환-8-알킬-7-옥소-7,8-디하이드로피리도[2,3-ｄ] 피리미딘-6-카르보니트릴 및 이의 용도
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
EP2646448B1 (de) 2010-11-29 2017-08-30 OSI Pharmaceuticals, LLC Makrocyclische kinasehemmer
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
CA2830516C (en) 2011-03-23 2017-01-24 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
JP5974084B2 (ja) * 2011-05-17 2016-08-23 プリンシピア バイオファーマ インコーポレイテッド チロシンキナーゼ阻害剤
WO2013126656A1 (en) * 2012-02-23 2013-08-29 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
RU2619944C2 (ru) * 2013-02-21 2017-05-22 Пфайзер Инк. Твердые формы селективного ингибитора CDK4/6
WO2015011236A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
JP6631616B2 (ja) * 2014-07-26 2020-01-15 ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド ＣＤＫ阻害剤としての２−アミノ−ピリド［２，３−ｄ］ピリミジン−７（８Ｈ）−オン誘導体及びその使用
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
TWI646094B (zh) * 2016-06-01 2019-01-01 大陸商貝達藥業股份有限公司 Crystal form of inhibitory protein kinase active compound and application thereof
EP3497103B1 (de) 2016-08-15 2021-05-05 Pfizer Inc. Pyridopyrimdinon-cdk2/4/6-inhibitoren
EP3589634A4 (de) * 2017-03-03 2020-08-12 Auckland Uniservices Limited Fgfr-kinase-inhibitoren und pharmazeutische verwendungen
AU2019220746A1 (en) 2018-02-15 2020-08-27 Nuvation Bio Inc. Heterocyclic compounds as kinase inhibitors
US20220024916A1 (en) * 2018-12-07 2022-01-27 Hangzhou Innogate Pharma Co., Ltd. Heterocyclic comipound as cdk-hdac dual pathway inhibitor
CN112759589B (zh) * 2019-11-01 2022-04-08 暨南大学 嘧啶并吡啶酮类化合物及其应用
US11697648B2 (en) 2019-11-26 2023-07-11 Theravance Biopharma R&D Ip, Llc Fused pyrimidine pyridinone compounds as JAK inhibitors
WO2022188755A1 (zh) * 2021-03-08 2022-09-15 暨南大学 吡啶并嘧啶类化合物及其应用
CN117720531A (zh) * 2022-09-16 2024-03-19 华东师范大学 作为rsk抑制剂的吡啶酮并嘧啶衍生物及其应用
WO2024099403A1 (zh) * 2022-11-10 2024-05-16 北京普祺医药科技股份有限公司 一种具有软药性质的硫醚类化合物、药物组合物及其用途
WO2024107730A1 (en) * 2022-11-14 2024-05-23 Onconova Therapeutics, Inc. Methods and compositions for treating cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
WO1998033798A2 (en) * 1997-02-05 1998-08-06 Warner Lambert Company Pyrido[2,3-d]pyrimidines and 4-amino-pyrimidines as inhibitors of cell proliferation
BR9911590A (pt) * 1998-05-26 2001-02-13 Warner Lambert Co Pirimidinas bicìclicas e 3,4-diidropirimidinas bicìclicas como inibidores da proliferação celular

Also Published As

Publication number Publication date
EA200200802A1 (ru) 2003-02-27
AU2001233028A1 (en) 2001-10-03
KR20020075805A (ko) 2002-10-05
BG107161A (en) 2003-06-30
IS6524A (is) 2002-08-23
HN2001000040A (es) 2001-09-06
HUP0300136A2 (en) 2003-05-28
CR6736A (es) 2004-03-10
IL151480A0 (en) 2003-04-10
GT200100037A (es) 2002-03-04
MXPA02008535A (es) 2002-12-13
TNSN01036A1 (en) 2005-11-10
MA26881A1 (fr) 2004-12-20
CN1422268A (zh) 2003-06-04
NO20024235D0 (no) 2002-09-05
PA8513201A1 (es) 2003-06-30
YU66502A (sh) 2005-09-19
SV2001000338A (es) 2001-11-30
EP1268476A1 (de) 2003-01-02
JP2003528101A (ja) 2003-09-24
AP2002002643A0 (en) 2002-12-31
NO20024235L (no) 2002-11-05
EE200200506A (et) 2004-02-16
CA2401368A1 (en) 2001-09-27
BR0109056A (pt) 2003-06-03
CZ20022929A3 (cs) 2003-02-12
HRP20020798A2 (en) 2004-02-29
NZ520962A (en) 2003-09-26
WO2001070741A1 (en) 2001-09-27
OA12227A (en) 2004-03-18
AR034119A1 (es) 2004-02-04
CO5280200A1 (es) 2003-05-30
PE20011177A1 (es) 2001-11-23
SK12472002A3 (sk) 2003-04-01
ZA200207110B (en) 2003-12-04
PL358271A1 (en) 2004-08-09

Similar Documents

Publication Publication Date Title
DZ3308A1 (de) 5-alkylpyrido [2,3-d] pyrimidin tyrosine kinase inhibitoren
EG24381A (en) Tyrosine kinase inhibitors
EP1161433A4 (de) Tyrosin-kinase-inhibitoren
HK1049154A1 (zh) 作為酪氨酸激酶抑制劑的2-吡唑啉-5-酮
AU2000240570A1 (en) Pyrrolopyrimidines as tyrosine kinase inhibitors
EE200200405A (et) Pürido[2,3-d]pürimidiin-2,7-diamiinid kui kinaasiinhibiitorid
IL159832A0 (en) 4-amino-6-phenyl-pyrrolo[2,3-d] pyrimidine derivatives
MXPA03008690A (es) Inhibidores novedosos de tirosina cinasa.
IL151104A0 (en) Kinase inhibitors
AU2002361577A1 (en) Tyrosine kinase inhibitors
EP1259236A4 (de) Tyrosinkinase-inhibitoren
AU2002348394A1 (en) Tyrosine kinase inhibitors
AU2002348020A1 (en) Tyrosine kinase inhibitors
AU2002348393A1 (en) Tyrosine kinase inhibitors
PL358551A1 (en) 5-aminoalkyl-pyrazolo[4,3-d]pyrimidines
AU2002323406A1 (en) Tyrosine kinase inhibitors
AU2002327534A1 (en) Tyrosine kinase inhibitors
AU8578501A (en) 2-aminoalkyl-thieno(2,3-d)pyrimidines
GB0013807D0 (en) Tyrosine kinase modulators
AU2002322568A1 (en) Tyrosine kinase inhibitors
AU2002326760A1 (en) Tyrosine kinase inhibitors
AU2002326466A1 (en) Tyrosine kinase inhibitors
AU2002327619A1 (en) Tyrosine kinase inhibitors
AU2002355733A1 (en) Tyrosine kinase inhibitors
AU2002337972A1 (en) Tyrosine kinase inhibitors